Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group
Timothy R. Rebbeck(Cancer Prevention Institute of California), Barbara Weber(Fox Chase Cancer Center), Laura van ‘t Veer, Theresa Wagner(Fox Chase Cancer Center), Katrina Armstrong(Columbia University), Gail E. Tomlinson(Fox Chase Cancer Center), Olufunmilayo I. Olopade(University of Chicago), Susan L. Neuhausen(City of Hope), Susan M. Domchek(University of Pennsylvania), Andrea Eisen(Regional Municipality of Durham), Claudine Isaacs(Fox Chase Cancer Center), D. Gareth Evans(Institute of Cancer Research), Steven A. Narod(University of Toronto), Judy E. Garber(Fox Chase Cancer Center), Mary B. Daly(Fox Chase Cancer Center), Ellen Matloff(Fox Chase Cancer Center), Tara M. Friebel(Fox Chase Cancer Center), Henry T. Lynch(Creighton University), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust)
Cited by 406
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Mutation of a <i>mutL</i> Homolog in Hereditary Colon Cancer
|Science|1994|1.8k